The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

International Journal of Cancer

Volumn 127, Issue 9, 2010, Pages 2209-2221

  Heiss, Markus M ^a   Murawa, Pawel ^b   Koralewski, Piotr ^c   Kutarska, Elzbieta ^d   Kolesnik, Olena O ^e   Ivanchenko, Vladimir V ^f   Dudnichenko, Alexander S ^g   Aleknaviciene, Birute ^h   Razbadauskas, Arturas ⁱ   Gore, Martin ^j   Ganea Motan, Elena ^f   Ciuleanu, Tudor ^k   Wimberger, Pauline ^l   Schmittel, Alexander ^m   Schmalfeldt, Barbara ⁿ   Burges, Alexander ^o   Bokemeyer, Carsten ^p   Lindhofer, Horst ^q   Lahr, Angelika ^r   Parsons, Simon L ^s  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

^b Wielkoposka Cancer Center   (Poland)

^c Rydygier Memorial Hospital   (Poland)

^d Centrum Onkologii Ziemi Lubelskiej   (Poland)

^e STATE INSTITUTION NATIONAL RESEARCH CENTER FOR RADIATION MEDICINE OF THE NATIONAL ACADEMY OF MEDICAL SCIENCES OF UKRAINE   (Ukraine)

^f Regional Clinical Oncology Dispensary ^*  (Romania)

^g KHARKIV MEDICAL ACADEMY OF POSTGRADUATE EDUCATION   (Ukraine)

^h VILNIUS UNIVERSITY   (Lithuania)

ⁱ Klaipeda Seamen's Hospital   (Lithuania)

^j ROYAL MARSDEN HOSPITAL   (United Kingdom)

^k Cancer Institute Ion Chiricuta Cluj Napoca   (Romania)

^l UNIVERSITY OF DUISBURG ESSEN   (Germany)

^m CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

ⁿ TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^o LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^p UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^q TRION Pharma GmbH   (Germany)

^r Fresenius Biotech   (Germany)

^s NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

more..

Author keywords

catumaxomab; clinical trial; epithelial cancer; malignant ascites; trifunctional antibody

Indexed keywords

CATUMAXOMAB; BISPECIFIC ANTIBODY;

ADULT; AGED; ARTICLE; ASCITES TUMOR; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OVARY CANCER; OVERALL SURVIVAL; PARACENTESIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; STOMACH CANCER; ASCITES; DRUG ADMINISTRATION; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NEOPLASM; PHASE 3 CLINICAL TRIAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, BISPECIFIC; ASCITES; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; HUMANS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; PARACENTESIS;

EID: 77954676136     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25423     Document Type: Article

References (40)

1. Parsons SL, Watson SA, Steele RJC,. Malignant ascites. Br J Surg 1996; 83: 6 -14.
2. Muir JC,. Ascites. In:, Von Roenn J, Smith TJ, Loprinzi CL, Von Gunten CF, eds. ASCO curriculum: optimizing cancer care. The importance of symptom management, vol. 1. Dubuque, IA: Kendall/Hunt, 2001. 1 -31.
3. Ayantunde AA, Parsons S,. Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann Oncol 2007; 18: 945 -9.
4. Tamsma J,. The pathogenesis of malignant ascites. Cancer Treat Res 2007; 134: 109 -18.
5. Preston N,. New strategies for the management of malignant ascites. Eur J Cancer Care 1995; 4: 178 -83.
6. Hostetter RB, Marincola FM, Schwarzentruber DJ,. Malignant ascites. In:, deVita VT, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology, 7th edn. Philadelphia: Lippincott-Williams & Wilkins, 2005. 2392 -8.
7. Becker G, Galandi D, Blum HE,. Malignant ascites: systematic review and guideline for treatment. Eur J Cancer 2006; 42: 589 -97.
8. Garrison RN, Kaelin LD, Galloway RH, Heuser LS,. Malignant ascites. Clinical and experimental observations. Ann Surg 1986; 203: 644 -51.
9. Ayhan A, Gultekin M, Taskiran C, Dursun P, Firat P, Bozdag G, Celik NY, Yuce K,. Ascites and epithelial ovarian cancers: a reappraisal with respect to different aspects. Int J Gynecol Cancer 2007; 17: 68 -75.
10. Lee CW, Bociek G, Faught W,. A survey of practice in the management of malignant ascites. J Pain Symptom Manage 1998; 16: 96 -101.
11. Smith EM, Jayson GC,. The current and future management of malignant ascites. Clin Oncol (R Coll Radiol) 2003; 15: 59 -72.
12. Ruf P, Lindhofer H,. Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood 2001; 98: 2526 -34.
13. Zeidler R, Mysliwietz J, Csnady M, Walz A, Ziegler I, Schmitt B, Wollenberg B, Lindhofer H,. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer 2000; 83: 261 -6.
14. Ruf P, Gires O, Jger M, Fellinger K, Atz J, Lindhofer H,. Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer. Br J Cancer 2007; 97: 315 -21.
15. Went PT, Lugli A, Meier S, Bundi M, Mirlacher M, Sauter G, Dirnhofer S,. Frequent EpCAM protein expression in human carcinomas. Hum Pathol 2004; 35: 122 -8.
16. Passebosc-Faure K, Li G, Lambert C, Cottier M, Gentil-Perret A, Fournel P, Pérol M, Genin C,. Evaluation of a panel of molecular markers for the diagnosis of malignant serous effusions. Clin Cancer Res 2005; 11: 6862 -7.
17. De Angelis M, Buley ID, Heryet A, Gray W,. Immunocytochemical staining of serous effusions with the monoclonal antibody Ber-EP4. Cytopathology 1992; 3: 111 -7.
18. Diaz-Arias AA, Loy TS, Bickel JT, Chapman RK,. Utility of BER-EP4 in the diagnosis of adenocarcinoma in effusions: an immunocytochemical study of 232 cases. Diagn Cytopathol 1993; 9: 516 -21.
19. McLaughlin PM, Harmsen MC, Dokter WH, Kroesen BJ, van der Molen H, Brinker MG, Hollema H, Ruiters MH, Buys CH, de Leij LF,. The epithelial glycoprotein 2 (EGP-2) promoter-driven epithelial-specific expression of EGP-2 in transgenic mice: a new model to study carcinoma-directed immunotherapy. Cancer Res 2001; 61: 4105 -11.
20. Okamoto S, Ito K, Sasano H, Moriya T, Niikura H, Terada Y, Sato S, Okamura K, Yaegashi N,. Ber-EP4 and anti-calretinin antibodies: a useful combination for differential diagnosis of various histological types of ovarian cancer cells and mesothelial cells. Tohoku J Exp Med 2005; 206: 31 -40.
21. Heiss MM, Ströhlein MA, Jger M, Kimmig R, Burges A, Schoberth A, Jauch KW, Schildberg FW, Lindhofer H,. Immunotherapy of malignant ascites with trifunctional antibodies. Int J Cancer 2005; 117: 435 -43.
22. Burges A, Wimberger P, Kmper C, Gorbounova V, Sommer H, Schmalfeldt B, Pfisterer J, Lichinitser M, Makhson A, Moiseyenko V, Lahr A, Schulze E, et al. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study. Clin Cancer Res 2007; 13: 3899 -905.
23. Likert R,. A technique for the measurement of attitudes. Arch Psychol 1932; 140: 1 -55.
24. Sartori S, Nielsen I, Tassinari D, Trevisani L, Abbasciano V, Malacarne P,. Evaluation of a standardized protocol of intracavitary recombinant interferon alpha-2b in the palliative treatment of malignant peritoneal effusions. A prospective pilot study. Oncology 2001; 61: 192 -6.
25. Stuart GC, Nation JG, Snider DD, Thunberg P,. Intraperitoneal interferon in the management of malignant ascites. Cancer 1993; 71: 2027 -30.
26. Hirte HW, Miller D, Tonkin K, Findlay B, Capstick V, Murphy J, Buckman R, Carmichael J, Levine M, Hill W,. A randomized trial of paracentesis plus intraperitoneal tumor necrosis factor-alpha versus paracentesis alone in patients with symptomatic ascites from recurrent ovarian carcinoma. Gynecol Oncol 1997; 64: 80 -7.
27. Ruth U, Kaufmann M, Schmid H, Hofmann J, Wiedenmann B, Kist A, Kempeni J, Schlick E, Bastert G, Kommerell B, M;nnel D,. Effect of intraperitoneal recombinant human tumour necrosis factor alpha on malignant ascites. Eur J Cancer 1991; 27: 121 -5.
28. Parsons SL, Watson SA, Steele RJ,. Phase I/II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites. Eur J Surg Oncol 1997; 23: 526 -31.
29. Katano M, Morisaki T,. The past, the present and future of the OK-432 therapy for patients with malignant effusions. Anticancer Res 1998; 18: 3917 -25.
30. Hamilton CA, Maxwell GL, Chernofsky MR, Bernstein SA, Farley JH, Rose GS,. Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer. Gynecol Oncol 2008; 111: 530 -2.
31. Kesterson JP, Mhawech-Fauceglia P, Lele S,. The use of bevacizumab in refractory ovarian granulosa-cell carcinoma with symptomatic relief of ascites: a case report. Gynecol Oncol 2008; 111: 527 -9.
32. Marmé A, Strauss G, Bastert G, Grischke EM, Moldenhauer G,. Intraperitoneal bispecific antibody (HEA125xOKT3) therapy inhibits malignant ascites production in advanced ovarian carcinoma. Int J Cancer 2002; 101: 183 -9.
33. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA,; Gynecologic OncologyGroup. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006; 354: 34 -43.
34. Jeyarajah DR, Thistlethwaite JR Jr., General aspects of cytokine-release syndrome: timing and incidence of symptoms. Transplant Proc 1993; 25: 16 -20.
35. Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A,. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab. IDEC-C2B8). Blood 1999; 94: 2217 -24.
36. Bokemeyer C, Heiss M, Gamperl H, Linke R, Schulze E, Friccius-Quecke H, Lindhofer H, Parsons S,. Safety of catumaxomab: cytokine-release-related symptoms as a possible predictive factor for efficacy in a pivotal phase II/III trial in malignant ascites. J Clin Oncol 2009; 27 (Suppl):Abstract 3036.
37. Prandota J,. Important role of proinflammatory cytokines/other endogenous substances in drug-induced hepatotoxicity: depression of drug metabolism during infections/inflammation states, and genetic polymorphisms of drug-metabolizing enzymes/cytokines may markedly contribute to this pathology. Am J Ther 2005; 12: 254 -61.
38. Molema G, Cohen-Tervaer JW, Kroesen BJ, Helfrich W, Meijer DK, de Leij LF,. CD3 directed bispecific antibodies induce increased lymphocyte-endothelia l cell interactions in vitro. Br J Cancer 2000; 82: 472 -9.
39. DeNardo GL, Mirick GR, Kroger LA, Bradt BM, Lamborn KR, DeNardo SJ,. Characterization of human IgG antimouse antibody in patients with B-cell malignancies. Clin Cancer Res 2003; 9: 4013 -4021S.
40. Miotti S, Negri DR, Valota O, Calabrese M, Bolhuis RL, Gratama JW, Colnaghi MI, Canevari S,. Level of anti-mouse-antibody response induced by bi-specific monoclonal antibody OC/TR in ovarian-carcinoma patients is associated with longer survival. Int J Cancer 1999; 84: 62 -8.